According to FutureWise analysis the market for neuroblastoma treatment in 2023 is US$ 0.49 billion, and is expected to reach US$ 0.68 billion by 2031 at a CAGR of 4.32%.
Neuroblastoma is a form of cancer that starts in nerve tissue cells. Neuroblasts are a type of cell that most commonly affects youngsters but can also impact adults. Neuroblastoma can affect any part of the body, although the abdomen is the most prevalent location. This malignancy frequently manifests as a single tumour or several tumours that grow fast and create major medical problems such as hydrocephalus (excessive fluid on the brain), spinal compression (nerve compression), or organ damage owing to adjacent metastases (spreading of cancer to other organs). The treatment for neuroblastoma varies depending on the stage of the cancer. There are three stages: localized (only in one spot), regional (in several locations), and metastatic (in multiple locations) (spread to another part of the body).
Localized cancers will be surgically removed and treated with chemotherapy and radiation. If the tumour is regional, it will be surgically removed by chemotherapy or surgery, depending on the disease's location. Monoclonal antibody treatment is a type of biotherapy or immunotherapy that uses monoclonal antibodies. It entails using monoclonal antibodies to combat malignant cells by either limiting their growth or selectively killing them (to reduce side effects). Monoclonal antibodies are frequently used in combination with other treatments such chemotherapy, radiotherapy, or the creation of new biologics. Chemotherapy is a cancer treatment that involves the administration of two or more anticancer medicines, each having its own mechanism of action. It's often used to treat tumours caused by genetic changes (e.g., mutations, chromosome translocations) for which no particular anti-cancer medicines exist.
FutureWise Market Research has instantiated a report that provides an intricate analysis of Neuroblastoma Treatment Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Neuroblastoma Treatment Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.